IRadimed Corporation
IRadimed Corporation (IRMD) Financial Performance & Income Statement Overview
Analyze IRadimed Corporation (IRMD) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
IRadimed Corporation (IRMD) Income Statement & Financial Overview
Review IRadimed Corporation IRMD income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $19.51M | $19.39M | $18.33M | $17.93M |
| Cost of Revenue | $4.67M | $4.63M | $4.13M | $3.92M |
| Gross Profit | $14.84M | $14.76M | $14.19M | $14.010M |
| Gross Profit Ratio | $0.76 | $0.76 | $0.77 | $0.78 |
| R&D Expenses | $624245.00 | $569993.00 | $639467.00 | $801129.00 |
| SG&A Expenses | $8.79M | $8.39M | $7.76M | $7.58M |
| Operating Expenses | $9.41M | $8.96M | $8.40M | $8.38M |
| Total Costs & Expenses | $14.08M | $18.46M | $12.54M | $12.30M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $0.00 | $194866.00 | $0.00 | $199130.00 |
| EBITDA | $5.43M | $5.92M | $5.79M | $5.63M |
| EBITDA Ratio | $0.28 | $0.31 | $0.32 | $0.31 |
| Operating Income | $5.43M | $5.80M | $5.79M | $5.63M |
| Operating Income Ratio | $0.28 | $0.30 | $0.32 | $0.31 |
| Other Income/Expenses (Net) | $513973.00 | $544160.00 | $629201.00 | $642217.00 |
| Income Before Tax | $5.95M | $6.34M | $6.42M | $6.27M |
| Income Before Tax Ratio | $0.30 | $0.33 | $0.35 | $0.35 |
| Income Tax Expense | $1.26M | $1.20M | $1.37M | $1.37M |
| Net Income | $4.69M | $5.15M | $5.05M | $4.90M |
| Net Income Ratio | $0.24 | $0.27 | $0.28 | $0.27 |
| EPS | $0.37 | $0.41 | $0.40 | $0.39 |
| Diluted EPS | $0.37 | $0.40 | $0.40 | $0.38 |
| Weighted Avg Shares Outstanding | $12.71M | $12.68M | $12.67M | $12.66M |
| Weighted Avg Shares Outstanding (Diluted) | $12.83M | $12.78M | $12.78M | $12.76M |
Financial performance has remained strong, with revenue growing from $17.93M in Q2 2024 to $19.51M in Q1 2025. Gross profit continued to perform well, with margins at 76% in the latest quarter. Operating income reached $5.43M in Q1 2025, holding a steady 28% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at $5.43M. Net income dropped to $4.69M, keeping EPS at $0.37. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan